In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild-type, unknown status of EGFR, or with EGFR activating mutations (Mountain 1997), to assess in terms of OS and PFS the clinical efficacy

of third-line chemotherapy compared to placebo or best supportive care,

third-line targeted therapy compared to placebo or best supportive care,

the third-line combination of chemotherapy and targeted therapy compared to placebo or best supportive care; and

to assess the relative efficacy of third-line chemotherapy compared to targeted therapy.